{"id":"W4379797826","doi":"10.1136/annrheumdis-2023-eular.3238","title":"AB1104 STRINGENT DISEASE ACTIVITY CONTROL AT 2 YEARS ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE CHARACTERISTICS IN PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY","year":2023,"lang":"en","type":"article","venue":"","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"Sanofi Genzyme; Bausch Health; Agencia Estatal de Investigación; Memorial University of Newfoundland; Sanofi; Kyowa Hakko Kirin; Celltrion; National Psoriasis Foundation; Pfizer; Biogen; Incyte; Castle Biosciences; Sun Pharma; Dermira; Regeneron Pharmaceuticals; Helsinn; Celgene; LEO Pharma; Ortho Dermatologics; Gilead Sciences; Galderma; XBiotech; Brigham and Women's Hospital; GlaxoSmithKline; Bristol-Myers Squibb; Eli Lilly and Company; Meiji Seika Pharma; Coherus Biosciences; UCB Pharma; Valeant Pharmaceuticals International; Helsinn Therapeutics; Amgen","keywords":"Medicine; Psoriatic arthritis; Dactylitis; Internal medicine; Placebo; Rheumatology; Ustekinumab; Clinical endpoint; Post-hoc analysis; Randomized controlled trial; Psoriasis; Enthesitis; Arthritis; Physical therapy; Disease; Immunology; Adalimumab; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008186481,0.002197874,0.005541457,0.0005286295,0.0005741116,0.001488701,0.001168644,0.001489115,0.004842298],"category_scores_gemma":[0.003976562,0.0008041445,0.005212843,0.000677517,0.001674092,0.001394029,0.0007510626,0.003241895,0.0007635626],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008422571,"about_ca_system_score_gemma":0.002348759,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008278069,"about_ca_topic_score_gemma":0.001577544,"domain_scores_codex":[0.9964865,0.002235136,0.0002457326,0.0004070706,0.0002317333,0.0003937286],"domain_scores_gemma":[0.996694,0.001174647,0.0007347095,0.0004739653,0.0002633226,0.0006593819],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9892224,0.003653094,0.0006073287,0.0001381802,0.001230067,0.00001246092,0.00002087027,0.0001853144,0.001219331,0.00002441248,0.0002012685,0.003485286],"study_design_scores_gemma":[0.7246698,0.2627894,0.007792756,0.00002142023,0.002627114,0.00002443388,0.00004197675,0.0006618883,0.0007472372,0.000121812,0.0004712398,0.00003093891],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921604,0.001525151,0.000808137,0.0002624204,0.0003522267,0.002678835,0.00115945,0.00008246425,0.0009709665],"genre_scores_gemma":[0.9902701,0.0008608929,0.001509767,0.0005102845,0.0004726916,0.003550112,0.001346614,0.00003246863,0.001447113],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008186481,"threshold_uncertainty_score":0.04329473,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01370864123754903,"score_gpt":0.2778400634311458,"score_spread":0.2641314221935968,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}